AMUN-003 / AmunBio, Endeavor Health Evanston Hospital - LARVOL DELTA

Oncolytic adenovirus inhibits TNBC tumor growth/metastasis in mice by targeting TGFB and overexpressing GM-CSF. (PubMed, Mol Ther Oncol) - "Thus, we developed a new oncolytic adenovirus rAd.sT.GM (AMUN-003) that expresses both sTGFβRIIFc (a TGF-β decoy), and GM-CSF and tested it in a mouse TNBC (4T1) subcutaneous model...We found several key anti-tumor Th1 cytokines such as interleukin (IL)-2, IL-4, and interferon-γ, were stimulated by the combination therapy either systemically or in tumors or both, as well as anti-tumor biomarkers such as Granzyme B and perforin. These results support advancement to clinical testing with the combination therapy of rAd.sT.GM and ICIs for TNBC patients."

IO biomarker • Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CSF2 • GZMB • IFNG • IL4 • TGFB1

Immune response markers following combination treatment with oncolytic adenovirus AMUN-003 and immune checkpoint inhibitors in a murine model of triple negative breast cancer (AACR 2023) - "The “Triplet” combination of AMUN-003, anti-PD1 and anti-CTLA-4 antibodies was associated with decrease of poor prognosis biomarkers in serum: TGF-β1: Triplet p< 0.001, ICIs p<0.01, AMUN-003 p< 0.05; IL-27p28/IL-30: Triplet and ICIs p< 0.05; IL-1β: Triplet, AMUN-003, ICIs, and AMUN-003+anti-CTLA-4 p< 0.05; TNF-α: Triplet p< 0.01, ICIs p<0.05, and increase of immune stimulatory IFN-γ: Triplet p<0.01 (all compared to the buffer). In lung tissue, no significant changes in cytokine/chemokine expression were detected, however Granzyme B levels were significantly increased in Triplet: p< 0.05. In spleen, we detected increased cytokine expression (IL-2: Triplet, anti-CTLA-4, AMUN-003+anti-PD-1 p< 0.05; IL-4: Triplet p< 0.001, AMUN-003+anti-PD-1, AMUN-003+anti-CTLA-4: p< 0.01)."

Checkpoint inhibition • IO biomarker • Oncolytic virus • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CXCR4 • GZMB • IFNG • IL1B • IL2 • IL4 • TGFB1 • TNFA

Targeting TGF-β and over-expressing GM-CSF in the Tumor Microenvironment (TME) with AMUN-003 Inhibits Tumor Growth and Metastases and Augments Immune Checkpoint Inhibitor (ICI) Response in Triple Negative Breast Cancer (TNBC) (SABCS 2022) - "In syngeneic immune competent animals harboring an aggressive TNBC tumor, single agent Amun-003 appeared safe and was more effective at controlling tumor progression following an intratumoral injection when compared to other tested adenovirus constructs. In the same model, combinations of ICI with Amun-003 resulted in delayed tumor growth and control of metastatic spread. These results with Amun- 003 support advancement to human clinical testing."

Biomarker • Checkpoint inhibition • IO biomarker • Tumor microenvironment • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CSF2 • IL6 • TGFB1

AmunBio to Present Scientific Data for AMUN-003 at the 2022 San Antonio Breast Cancer Symposium (SABCS) (PRWeb) - "AmunBio, Inc....announced a presentation, on Tuesday, December 6, 2022, at the 45th annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Tx., of the pre-clinical study results of AMUN-003...being developed for the treatment of multiple solid tumors, including aggressive, metastasized, triple-negative breast cancer (TNBC)....'AMUN-003 is an advanced generation oncolytic adenovirus that selectively enters cancer cells followed by viral reproduction and destruction of the cancer cell on exit....Our data, which will be presented at SABCS this year, shows that in a highly aggressive TNBC model AMUN-003 demonstrates single agent safety and efficacy. Moreover, in the same TNBC model, combination therapy with immune Checkpoint Inhibitors synergizes with the AMUN-003, resulting in significant inhibition of further metastatic spread. Additional pre-clinical studies are underway to advance this technology into clinical trials.'"

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer